PT - JOURNAL ARTICLE AU - Toshiyuki Nagai AU - Varun Sundaram AU - Kieran Rothnie AU - Jennifer Kathleen Quint AU - Ahmad Shoaib AU - Yasuyuki Shiraishi AU - Shun Kohsaka AU - Susan Piper AU - Theresa A McDonagh AU - Suzanna Marie C Hardman AU - Ayumi Goda AU - Atsushi Mizuno AU - Takashi Kohno AU - Alan S Rigby AU - Tsutomu Yoshikawa AU - Andrew L Clark AU - Toshihisa Anzai AU - John G F Cleland TI - Mortality after admission for heart failure in the UK compared with Japan AID - 10.1136/openhrt-2018-000811 DP - 2018 Aug 01 TA - Open Heart PG - e000811 VI - 5 IP - 2 4099 - http://openheart.bmj.com/content/5/2/e000811.short 4100 - http://openheart.bmj.com/content/5/2/e000811.full SO - Open Heart2018 Aug 01; 5 AB - Objective Mortality amongst patients hospitalised for heart failure (HHF) in Western and Asian countries may differ, but this has not been investigated using individual patient-level data (IPLD). We sought to remedy this through rigorous statistical analysis of HHF registries and variable selection from a systematic literature review.Methods and results IPLD from registries of HHF in Japan (n=3781) and the UK (n=894) were obtained. A systematic literature review identified 23 models for predicting outcome of HHF. Five variables appearing in 10 or more reports were strongly related to prognosis (systolic blood pressure, serum sodium concentration, age, blood urea nitrogen and creatinine). To compare mortality in the UK and Japan, variables were imputed in a propensity model using inverse probability of treatment weighting (IPTW) and IPTW with logistic regression (doubly robust IPTW). Overall, patients in the UK were sicker and in-patient and post-discharge mortalities were greater, suggesting that the threshold for hospital admission was higher. Covariate-adjusted in-hospital mortality was similar in the UK and Japan (IPTW OR: 1.14, 95% CI 0.70 to 1.86), but 180-day postdischarge mortality was substantially higher in the UK (doubly robust IPTW OR: 2.33, 95% CI 1.58 to 3.43).Conclusions Despite robust methods to adjust for differences in patient characteristics and disease severity, HHF patients in the UK have roughly twice the mortality at 180 days compared with those in Japan. Similar analyses should be done using other data sets and in other countries to determine the consistency of these findings and identify factors that might inform healthcare policy and improve outcomes.